

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Initiate the application of: Dana M. Fowlkes, *et al.*

Serial No.: 09/258600

Filed: February 26, 1999

For: *Yeast Cells Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor*

Attorney Docket No.: CPI-012CP4DV

Group Art Unit: 1643

Examiner: Not Assigned

TECH CENTER 1600/2800

1600 2800
TECH CENTER

RECEIVED

Office of Initial Patent Examination Customer Service Center
Commissioner for Patents
Washington, DC 20231

Certificate of First Class Mailing (37 CFR 1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Office of Initial Patent Examination Customer Service Center, Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

December 13, 2002

Date of Signature and of Mail Deposit

By: 

Hathaway Pease, Esq., Reg. No. 46,488

ASSOCIATE POWER OF ATTORNEY


Sir:

The undersigned attorney has the power of attorney in the subject application. He hereby grants an associate power to:

Hathaway Pease, Esq.
Registration No. 46,488
Lahive & Cockfield, LLP
60 State Street
Boston, MA 02109


Please continue to forward all written and telephonic communications to Giulio A. DeConti, Jr. at the address and telephone number listed below.

Respectfully submitted,



Peter C. Lauro, Esq.
Registration No. 32,360
Attorney for Applicants

LAHIVE & COCKFIELD, LLP
60 State Street
Boston, MA 02109
Tel. (617) 227-7400



APRIL 19, 2002

PTAS

LAHIVE & COCKFIELD, LLP
PETER C. LAURO, ESQ.
28 STATE STREET
BOSTON, MA 02109

Chief Financial Officer and Chief Administrative Officer
Washington, DC 20231
www.uspto.gov



101994847A

UNITED STATES PATENT AND TRADEMARK OFFICE
NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT DIVISION OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE ASSIGNMENT SEARCH ROOM ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT AND TRADEMARK ASSIGNMENT SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR HAVE QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT DIVISION, BOX ASSIGNMENTS, CG-4, 1213 JEFFERSON DAVIS HWY, SUITE 320, WASHINGTON, D.C. 20231.

RECORDATION DATE: 02/11/2002

REEL/FRAME: 012598/0490

NUMBER OF PAGES: 10

BRIEF: ASSIGNMENT OF ASSIGNOR'S INTEREST (SEE DOCUMENT FOR DETAILS).

ASSIGNOR:

CADUS PHARMACEUTICAL CORPORATION

DOC DATE: 12/18/2001

ASSIGNEE:

CADUS TECHNOLOGIES, INC.
767 FIFTH AVENUE
NEW YORK, NEW YORK 10153

SERIAL NUMBER: 09309196
PATENT NUMBER:

FILING DATE: 05/10/1999
ISSUE DATE:

SERIAL NUMBER: 09286166
PATENT NUMBER:

FILING DATE: 04/05/1999
ISSUE DATE:

SERIAL NUMBER: 09143246
PATENT NUMBER:

FILING DATE: 08/28/1998
ISSUE DATE:

SERIAL NUMBER: 09258600
PATENT NUMBER:

FILING DATE: 02/26/1999
ISSUE DATE:

012598/0490 PAGE 2

SERIAL NUMBER: 09747774 PATENT NUMBER:	FILING DATE: 12/21/2000 ISSUE DATE:
SERIAL NUMBER: 09953354 PATENT NUMBER:	FILING DATE: 09/13/2001 ISSUE DATE:
SERIAL NUMBER: 08946298 PATENT NUMBER:	FILING DATE: 10/07/1997 ISSUE DATE:
SERIAL NUMBER: 09201396 PATENT NUMBER:	FILING DATE: 11/30/1998 ISSUE DATE:
SERIAL NUMBER: 09581861 PATENT NUMBER:	FILING DATE: 03/05/2001 ISSUE DATE:
SERIAL NUMBER: 09241888 PATENT NUMBER:	FILING DATE: 02/01/1999 ISSUE DATE:
SERIAL NUMBER: 09658765 PATENT NUMBER:	FILING DATE: 09/08/2000 ISSUE DATE:
SERIAL NUMBER: 09592010 PATENT NUMBER:	FILING DATE: 06/12/2000 ISSUE DATE:
SERIAL NUMBER: 09378046 PATENT NUMBER:	FILING DATE: 08/20/1999 ISSUE DATE:
SERIAL NUMBER: 09305923 PATENT NUMBER: 6355473	FILING DATE: 05/05/1999 ISSUE DATE: 03/12/2002
SERIAL NUMBER: 09362286 PATENT NUMBER:	FILING DATE: 07/27/1999 ISSUE DATE:
SERIAL NUMBER: 09527998 PATENT NUMBER:	FILING DATE: 03/17/2000 ISSUE DATE:
SERIAL NUMBER: 08322137 PATENT NUMBER: 6100042	FILING DATE: 10/13/1994 ISSUE DATE: 08/08/2000
SERIAL NUMBER: 08461598 PATENT NUMBER: 5876951	FILING DATE: 06/05/1995 ISSUE DATE: 03/02/1999
SERIAL NUMBER: 08464531 PATENT NUMBER: 5789184	FILING DATE: 06/05/1995 ISSUE DATE: 08/04/1998
SERIAL NUMBER: 08582333 PATENT NUMBER: 6255059	FILING DATE: 01/17/1996 ISSUE DATE: 07/03/2001
SERIAL NUMBER: 08732218 PATENT NUMBER: 6001553	FILING DATE: 01/14/1997 ISSUE DATE: 12/14/1999
SERIAL NUMBER: 08936632 PATENT NUMBER: 6159705	FILING DATE: 09/24/1997 ISSUE DATE: 12/12/2000

012598/0490 PAGE 3

SERIAL NUMBER: 09042853
PATENT NUMBER: 6251065

FILING DATE: 03/17/1998
ISSUE DATE: 06/26/2001

KIMBERLY WHITE, EXAMINER
ASSIGNMENT DIVISION
OFFICE OF PUBLIC RECORDS

FORM PTO-1595

(Rev. 3/01)
OMB No. 0651-0027 (exp. 5/31/2002)OCT 18 2002
DEC 18 2002

02-27-2002

Tab settings □ □ □

101994847

SHEET

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

△CPI-000

△

△

To the Honorable Commissioner of Patents and Trademarks: Please record the attached original documents or copy thereof.

1. Name of conveying party:

Cadus Pharmaceutical Corporation

JUL 11 2002

Additional name(s) of conveying party(ies) attached? Yes No

3. Nature of conveyance

- | | |
|--|---|
| <input checked="" type="checkbox"/> Assignment | <input type="checkbox"/> Merger |
| <input type="checkbox"/> Security Agreement | <input type="checkbox"/> Change of Name |
| <input type="checkbox"/> Other _____ | |

Execution Date: December 18, 2001

2. Name and address of receiving party:

Name: Cadus Technologies, Inc.

Internal Address: _____

Street Address: 767 Fifth Avenue

City: New York State: NY ZIP: 10153

Additional name(s) & address(es) attached? Yes No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is: _____

A. Patent Application No.(s)

1. 08/322,137 (6,100,042)
2. 09/309,196

B. Patent No.(s)

Additional numbers attached? Yes No

5. Name and address of party to whom correspondence concerning document should be mailed:

Name: Peter C. Lauro, Esq.

Internal Address: Lahive & Cockfield, LLP

Street Address: 28 State Street

City: Boston State: MA ZIP: 02109

6. Total number of applications and patents involved:

23

7. Total fee (37 CFR 3.41).....\$ \$920.00 Enclosed Authorized to be charged to deposit account

8. Deposit account number:

12-0080

(Attach duplicate copy of this page if paying by deposit account)

DO NOT USE THIS SPACE

9. Statement and signature.

To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a true copy of the original document.

Peter C. Lauro, Esq.

Name of Person Signing

Signature

January 11, 2002
Date

Total number of pages including cover sheet, attachments, and document:

10

02/26/2002 08:17 AM 0000088 08322137
Mail documents to be recorded with required cover sheet information to:
920.00 x Assignment, Director - U.S. Patent and Trademark Office
Washington, D.C. 20231

01 FC:581



Additional Application/Patent Numbers
CPI-000

A. Patent Application/Patent Numbers

3. 09/286,166
4. 09/143,246
5. 08/461,598 (5,876,951)
6. 09/258,600
7. 08/464,531 (5,789,184)
8. 08/582,333 (6,255,059)
9. 09/747,774
10. 09/953,354
11. 08/946,298
12. 09/201,396
13. 09/581,861
14. 08/732,218 (6,001,553)
15. 08/936,632 (6,159,705)
16. 09/241,888
17. 09/658,765
18. 09/592,010
19. 09/378,046
20. 09/305,923
21. 09/426,332 (6,251,605B1)
22. 09/362,286
23. 09/527,998

GENERAL ASSIGNMENT OF PATENT RIGHTS

WHEREAS, Cadus Pharmaceutical Corporation, a corporation with a place of business at 767 Fifth Avenue, New York, NY 10153 (hereinafter "ASSIGNOR"), is the owner of the entire right, title and interest in and to the patents and patent applications identified in Appendix A hereto;


WHEREAS, ASSIGNOR desires to sell, convey, transfer, assign, and deliver its entire interest in the patents and patent applications identified in Appendix A to its wholly-owned subsidiary, Cadus Technologies, Inc., a Delaware corporation ("ASSIGNEE");

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, ASSIGNOR, does hereby sell, convey, transfer, assign and deliver to ASSIGNEE the full and exclusive right, title and interest in and to the patents and patent applications identified in Appendix A hereto and any divisional, continuing, reissue or other applications based in whole or in part thereon. This Patent Assignment includes the right to pursue all claims for damages by reason of past infringement of any and all patents listed in Appendix A hereto with the right to sue for, and collect the same for its own use and for the use of its successors, assigns or other legal representatives as fully and entirely as the same would have been enjoyed by ASSIGNOR, if this assignment had not been made.


CADUS PHARMACEUTICAL CORPORATION

By Russell Glass
Russell D. Glass, President

Sworn to before me and subscribed in my presence this 18th day of December, 2001.


Notary Public

PAUL WOLFSON
NOTARY PUBLIC, State of New York
No. 01WO5024198
Qualified in Westchester County
Commission Expires March 7, 2002



Appendix A to General Assignment of Patent Rights

I. U.S. Applications/Patents

Attorney Docket No.	Serial No./ Patent No.	Title	Filing Date/ Issue Date/ Expiration Date	Status
CPI-012(CP3	08/322,137 6,100,042	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	10/13/94 8/8/00 8/8/17	ISSUED
CPI-012(CP3CN	09/309,196	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	5/10/99	PENDING
CPI-012(CP4BCN	09/286,166	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	4/5/99	PENDING
CPI-012(C4DVCPA	09/143,246	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	8/28/98 (CPA filed 6/28/00)	PENDING
CPI-012(CP4C	08/461,598 5,876,951	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	6/5/95 3/2/99 3/2/16	ISSUED
CPI-012(CP4DV	09/258,600	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	2/26/99	PENDING
CPI-012(CP4D	08/464,531 5,789,184	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	6/5/95 8/4/98 8/4/15	ISSUED
CPI-012(CP5	08/582,333 6,255,059	Methods and Composition for Identifying Receptor Effectors	1/17/96 7/03/01 8/8/17	ISSUED
CPI-012(CP5DV	09/747,774	Methods and Composition for Identifying Receptor Effectors	1/2/21/00	PENDING

JAN 1
RECEIVED
TECH CENTER 1600
U.S. PATENT AND TRADEMARK OFFICE

U.S. Applications/Patents (cont'd)

<i>Attorney Docket No.</i>	<i>Serial No./ Patent No.</i>	<i>Title</i>	<i>Filing/ Issue Date/ Expiration Date</i>	<i>Status</i>
'PI-012CP7(CPACN	09/953,354	Methods and Composition for Identifying Receptor Effectors	9/13/01	PENDING
'PI-012(CP8CPA	08/946,298	Yeast Cells Expressing Modified G Proteins and Methods of Use Therefor	10/07/97	PENDING
'PI-012(CP9	09/201,396	Methods and Compositions for Identifying Receptor Effectors	11/30/98	PENDING
'PI-012C8US	09/581,861	Yeast Cells Expressing Modified G Proteins and Methods of Use Therefor	10/7/98	PENDING
'PI-014US	08/732,218 6,001,553	Functional Expression of Mammalian Adenylyl Cyclase in Yeast	4/26/95 12/14/99 12/14/16	ISSUED
'PI-031CP2	08/936,632 6,159,705	Methods and Compositions for Identifying Receptor Effectors	9/24/97 12/12/00 9/24/16	ISSUED

U.S. Applications/Patents (cont'd)

<i>Attorney Docket No.</i>	<i>Serial No./ Patent No.</i>	<i>Title</i>	<i>Filing Date/ Issue Date/ Expiration Date</i>	<i>Status</i>
CPI-102	09/241,888	Cell Based Signal Generation	2/1/99	PENDING
CPI-122	09/658,765	Yeast Alpha Agglutinins and Use Thereof as Indicators of Activation of the Yeast Pheromone Response Pathway	9/08/00	PENDING
CPI-123	09/592,010	Mating Factor α System for Detection of a Functional Interaction Between A Compound and a Cellular Receptor	6/12/00	PENDING
CPI-088	09/378,046	Cells Having Amplified Signal Transduction Pathway Responses and Uses Therefor	8/30/99	PENDING
CPI-091	09/305,923	Yeast Cells Having Mutations in STP22 and Uses Therefor	5/5/99	PENDING
CPI-096	09/426,332 6,251,605B1	Yeast Cells Having Mutations in CAV1 and Uses Therefor	10/25/99 6/26/01 10/25/19	ISSUED

U.S. Applications/Parents (cont'd)

<i>Attorney Docket No.</i>	<i>Serial No./ Patent No.</i>	<i>Title</i>	<i>Filing Date/ Issue Date/ Expiration Date</i>	<i>Status</i>
CPI-099	09/362,286	Expression of G Protein Coupled Receptors with Altered Ligand Binding and/or Coupling Properties	7/27/99	PENDING
CPI-110	09/527,998	Methods for Identifying Target G Protein-Coupled Receptors Using Hidden Markoff Models	3/17/00	PENDING

II. International Applications/Patents

<i>Attorney Docket No.</i>	<i>Serial No./ Patent No.</i>	<i>Title</i>	<i>Filing Date/ Expiration Date/ Issue Date</i>	<i>Status</i>
CPI-012CPAU	64909/94 685103	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	3/23/94 4/30/98 3/23/14	GRANTED
CPI-012CPAUDV2	71696/00	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	11/16/00	PENDING
CPI-012CPPCA	2,158,274 2,158,274	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	3/23/94 5/30/00 3/23/14	GRANTED
CPI-012CPPEP	94912292.3 0692025	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	3/23/94 10/17/01 3/23/14	GRANTED Registration Pending for AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL and SE
CPI-012CPEPDV	98202997.7	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	9/8/98	PENDING
CPI-012CPJP	06-522167	Yeast Cell Engineered to Produce Pheromone System Protein Surrogates, and Uses Therefor	3/23/94	PENDING
CPI-012C8AU	97911/98	Yeast Cells Expressing Modified G Proteins and Methods of Use Therefor	10/7/98	PENDING
CPI-012C8CA	2305204	Yeast Cells Expressing Modified G Proteins and Methods of Use Therefor	10/7/98	PENDING

CPI-012C8EP	98 95 2143.0	Yeast Cells Expressing Modified G Proteins and Methods of Use Therefor	10/7/98	PENDING
-------------	--------------	--	---------	---------

International Applications/Patents (cont'd)

<i>Attorney Docket No.</i>	<i>Serial No./ Patent No.</i>	<i>Title</i>	<i>Filing Date/ Issue Date/ Expiration Date</i>	<i>Status</i>
CPI-012C8JP	2000-515008	Yeast Cells Expressing Modified G Proteins and Methods of Use Therefor	10/7/98	PENDING
CPI-014AU	26354/95 702075	Functional Expression of Mammalian Adenylyl Cyclase in Yeast	4/26/95 5/27/99 4/26/15	GRANTED
CPI-014CA	2,188,950 2,188,950	Functional Expression of Mammalian Adenylyl Cyclase in Yeast	4/26/95 7/03/01 4/26/15	GRANTED
CPI-014JP	528355/95	Functional Expression of Mammalian Adenylyl Cyclase in Yeast	4/26/95	PENDING
CPI-031C2AU	45930/97	Methods and Compositions for Identifying Receptor Effectors	9/24/97 8/16/01 733,007 9/24/17	GRANTED
CPI-031C2CA	2,266,543	Methods and Compositions for Identifying Receptor Effectors	9/24/97	PENDING
CPI-031C2EP	97 94 4430.4	Methods and Compositions for Identifying Receptor Effectors	9/24/97	PENDING
CPI-031C2JP	10-515880	Methods and Compositions for Identifying Receptor Effectors	9/24/97	PENDING

Two letter country code: AT = Austria; AU = Australia; BE = Belgium; CH = Switzerland; DE = Germany; DK = Denmark; EP = Europe (European Patent Convention); ES = Spain; FR = France; GB = Great Britain; GR = Greece; IE = Ireland; IT = Italy; JP = Japan; LU = Luxembourg; NL = Netherlands; SE = Sweden